|
Thomas' Biotech Briefing
Distilled Bio uses AI to process and generate content for you. Verify important details using the linked sources.
AI-generated briefing: BridgeBio awaits an FDA decision on a potential first limb-girdle muscular dystrophy therapy, while peptide compounding rules and HanchorBio’s Taiwan clearance draw attention.
The top 10 stories from Fri Oct 30, 2026 06:56 AM to Mon Nov 2, 2026 06:57 AM
Generated November 2, 2026 at 6:57 AM
|
|
|
#1 At least 11 PDUFAs on FDA’s November docket Published 2026-10-31 The FDA’s November docket includes at least 11 PDUFA dates, with PD-1/VEGF bispecific ivonescimab first on the schedule. Covered by: biocentury.com, insights.citeline.com |
#2 Gilead CAR-T on partial clinical hold; Agios' PDUFA date pushed back Published 2026-10-30 Gilead paused a CAR-T program after several cases of ICANS, while the FDA delayed Agios’ PDUFA date. Covered by: endpoints.news, fiercebiotech.com |
#3 Pink Sheet Podcast: Peptide Compounding’s Broader Implications; Industry Opposes CRL Release Published 2026-10-30 The FDA and pharmaceutical industry remain at odds over releasing complete response letters, while peptide compounding raises broader regulatory questions. Covered by: insights.citeline.com |
#4 After A Long Wait, Xbrane Gets FDA Approval For Lucentis Biosimilar Published 2026-10-30 The FDA approved Xbrane Biopharma’s Lucamzi (ranibizumab-blrz), a biosimilar to Lucentis, after multiple setbacks. Covered by: insights.citeline.com |
#5 Beyond Conventional Anti-TIGIT: HanchorBio Secures Taiwan TFDA Approval for HCB303 Following U.S. FDA Clearance Published 2026-10-30 HanchorBio received Taiwan TFDA approval for HCB303 after U.S. FDA clearance, advancing the trispecific TIGIT-Fc ligand trap toward multi-regional Phase 1 development. Covered by: prnewswire.com |
#6 AdComm Supports US FDA Verdict On Sydnexis’ Myopia Drug, Finds Trial And Literature Issues Published 2026-10-31 An FDA advisory committee supported the agency’s decision on Sydnexis’s myopia drug, citing issues with the clinical trial and supporting literature. Covered by: insights.citeline.com |
#7 BsUFA IV Facility Lifecycle Program Aims To Cut Biosimilar CRLs Through Earlier FDA Dialogue Published 2026-10-30 BsUFA IV’s Facility Lifecycle Program aims to reduce biosimilar manufacturing rejections by enabling earlier dialogue between manufacturers and the FDA. Covered by: insights.citeline.com |
#8 BridgeBio gears up for rare muscular dystrophy launch with FDA approval in sight Published 2026-11-02 The FDA is expected to decide by Nov. 27 whether to approve BridgeBio Pharma’s BBP-418, which could become the first therapy for limb-girdle muscular dystrophy. Covered by: biospace.com |
#9 Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System Published 2026-11-01 Abbott reported strong 30-day outcomes and high procedural success in the TECTONIC trial of its investigational SonicForce coronary lithotripsy system. Covered by: prnewswire.com |
#10 Zhimeng Biopharma has completed the patients enrollment of its investigational drug, CB03-154, in the pivotal Phase 2/3 ALS clinical trial. Published 2026-10-31 Zhimeng Biopharma completed patient enrollment in the pivotal Phase 2/3 trial of its investigational ALS drug, CB03-154. Covered by: prnewswire.com |
